Could a diabetes drug help detect Alzheimer's early?

NCT ID NCT03560960

Ongoing Diagnosis Sponsor: Boston University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether a single injection of pramlintide, a diabetes drug, can temporarily increase levels of Alzheimer's-related proteins in the blood, potentially revealing early signs of the disease. Researchers will measure changes in beta-amyloid and tau proteins before and after injection in 57 people with mild cognitive impairment, Alzheimer's, or normal cognition. The goal is to develop a simple, accessible blood test for early Alzheimer's detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pramlintide (Symlin)
What this could lead to: If successful, this could lead to a simple blood test for early Alzheimer's detection, helping diagnose the disease before severe symptoms appear.
What could go wrong: This is a very early, small study (57 people) testing a biomarker, not a treatment. The approach may not reliably distinguish early Alzheimer's from other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MILD COGNITIVE IMPAIRMENT

Contacts and locations

Locations

BU Alzheimer Disease Center

Boston, Massachusetts, 02118, United States
Indiana University Alzheimer Disease Center

Indianapolis, Indiana, 46202, United States
Memory Center VA Boston Healthcare

Jamaica Plain, Massachusetts, 02130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.